3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Burkitt Lymphoma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Lymphoma
1
Leukemia
1
Interventions
Cyclophosphamide
30
Rituximab
26
Biopsy
23
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
fludarabine
14
Prednisone
13
Vincristine
11
obinutuzumab
10
Lenalidomide
10
Etoposide
10
Doxorubicin
10
Bendamustine Hydrochloride
9
pembrolizumab
7
venetoclax
6
fludarabine phosphate
6
X-Rays
6
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Dexamethasone
6
Bortezomib
6
trametinib
5
ibrutinib
5
glofitamab
5
acalabrutinib
5
Mycophenolic Acid
5
Gemcitabine
5
Crizotinib
5
Busulfan
5
copanlisib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
tisagenlecleucel
×
90 days
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available